Xylyx Bio

Xylyx Bio partners with Inventia Life Science to develop tissue-specific, digitally-printed bioinks for drug discovery

Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research. Read more >>
Read more...

From Conquering COVID-19 to Curing Cancer, New York City Charts the Future of Life Sciences

For the past 25 years, the public and private sectors have worked together to establish New York City as a global leader in life sciences research and innovation. Thanks to that coordinated effort, the city was able to respond to COVID-19 efficiently and effectively, becoming a model for other urban areas as COVID-19 cases peaked across the U.S.—and showcasing a burgeoning life sciences industry in the city that’s poised for future growth... New York life sciences companies continue to step...
Read more...

XYLYX BIO launches specialized contract R&D services that increase predictiveness in antifibrotic drug discovery

Xylyx Bio, a leader in advanced disease models for drug discovery, today announced the launch of specialized contract R&D services that support improved assessment of antifibrotic drug candidate efficacy. Despite ongoing advances, the current drug discovery paradigm is highly inefficient. Read more >>
Read more...

Patient-Derived Organoids Transform Precision Medicine

Advances in cell culture techniques don’t just mean more accurate models, but more personal ones. For decades scientists have been trying to figure out how to grow cells, especially diseased ones, directly from patients, not only to better understand the mechanisms at play, but also to determine the best approach to cure or correct the malfunction. Today, scientists can grow human tumors in a variety of designer mice, some with human immune systems. Read more >>
Read more...

XYLYX BIO releases highly physiologic 2D substrates for improved antifibrotic drug discovery

New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH. Read more >>
Read more...

Allevi Partners with Xylyx Bio to Create Liver Specific Bioinks

...Only a handful of researchers and companies around the world are tackling liver-specific bioinks, and one of them is now Allevi. The Philadelphia-based biotech company has now partnered with Xylyx Bio, a pioneer in physiomimetic biomaterials, to introduce new tissue-specific bioinks with Decellularized Extracellular Matrix (dECM). Read more >>
Read more...